Raymond James upgraded GoodRx to Strong Buy from Outperform with an unchanged price target of $10. The 19% selloff post the Q2 report is overdone, the analyst tells investors in a research note. The firm says the market reacted to a $5M revenue guidance reduction due to Rite Aid post-bankruptcy store closures, a new development since the analyst day.Raymond James says GoodRx has weathered CVS store closures and the Walgreens closures “will be equally a non-event.” Additionally, it still thinks 2026 estimates are conservative.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx sees FY24 revenue at ‘low end’ of $800M-$810M, consensus $806.38M
- GoodRx sees Q3 revenue $193M-$197M, consensus $202.37M
- GoodRx reports Q2 adjusted EPS 8c, consensus 9c
- Boehringer Ingelheim, GoodRx enter exclusive patient affordability initiative
- GoodRx Holdings Board Restructure and New Director Induction
Questions or Comments about the article? Write to editor@tipranks.com